– IRELAND, Dublin – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Patrick Kennedy to its Board as a new Independent Director effective March 1, 2024, bringing over 30 years of experience to the Board with a successful track record across a range of global businesses.
Patrick Kennedy will also join the Audit Committee.
The company also announced that Peter Gray will not seek re-election to the Board at the next AGM in July 2024.
“We are thrilled to welcome Patrick to the Board. His wealth of experience leading some of Ireland’s most influential and successful organizations and well-established global track record with dynamic, growth-oriented companies is exceptionally aligned with Jazz’s focus on creating value for shareholders. I am confident that Patrick’s expertise will complement the capabilities of the existing Jazz Board as we aim to transform the lives of patients and their families,” said Chairman and CEO, Bruce Cozadd.
About Patrick Kennedy
Patrick Kennedy joined the Bank of Ireland’s Board of Directors in 2010 and has been chairing since 2018. He was the CEO of Paddy Power plc, a leading Irish brand, for nine years, was CFO of Greencore Group plc, and held prior roles with KPMG Corporate Finance and McKinsey & Company. Mr. Kennedy served as a non-executive director of Elan Corporation plc, a biotechnology company, and retailer ASOS plc. He is also the Chair and non-executive director of CarTrawler, a world-leading B2B technology platform for car rental and mobility solutions.
“I am impressed by the strength of Jazz’s business and the talent within the organization,” said Patrick Kennedy. “I am looking forward to the opportunity to work alongside my Board colleagues and the Company’s management to help guide the company’s future growth, and to deliver value to our shareholders and meaningful impact for patients.”
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities, and employees in multiple countries committed to serving patients worldwide.
SOURCE: www.jazzpharmaceuticals.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
